Mesa Laboratories MLAB Biopharmaceutical Development — Goodwill
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The official record: Mesa Laboratories’s 10-K, filed June 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mesa Laboratories's biopharmaceutical development — goodwill.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mesa Laboratories's biopharmaceutical development — goodwill?
- Mesa Laboratories (MLAB) reported biopharmaceutical development — goodwill of $49.67M in Q1 2026.
- How has Mesa Laboratories's biopharmaceutical development — goodwill changed year-over-year?
- Mesa Laboratories's biopharmaceutical development — goodwill increased by 3.0% year-over-year, from $48.21M to $49.67M.
- What is the long-term trend for Mesa Laboratories's biopharmaceutical development — goodwill?
- Over 2 years (2023 to 2026), Mesa Laboratories's biopharmaceutical development — goodwill has grown at a -21.4% compound annual growth rate (CAGR), from $324.72M to $200.43M.
- What does biopharmaceutical development — goodwill mean?
- Represents the intangible asset value recorded when the purchase price of an acquired business within the Biopharmaceutical Development segment exceeds the fair value of its identifiable net assets. This reflects the premium paid for synergies, brand reputation, and customer relationships. Monitoring this balance is essential for assessing the long-term value of historical acquisitions.